|
1
|
Singer M, Deutschman CS, Seymour CW,
Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche
JD, Coopersmith CM, et al: The third international consensus
definitions for sepsis and septic shock (sepsis-3). JAMA.
315:801–810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cohen J: The immunopathogenesis of sepsis.
Nature. 420:885–891. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Turner A, Tsamitros M and Bellomo R:
Myocardial cell injury in septic shock. Crit Care Med.
27:1775–1780. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beesley SJ, Weber G, Sarge T, Nikravan S,
Grissom CK, Lanspa MJ, Shahul S and Brown SM: Septic
cardiomyopathy. Crit Care Med. 46:625–634. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blanco J, Muriel-Bombín A, Sagredo V,
Taboada F, Gandía F, Tamayo L, Collado J, García-Labattut A,
Carriedo D, Valledor M, et al: Incidence, organ dysfunction and
mortality in severe sepsis: A Spanish multicentre study. Crit Care.
12:R1582008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martinon F, Burns K and Tschopp J: The
inflammasome: A molecular platform triggering activation of
inflammatory caspases and processing of proIL-beta. Mol Cell.
10:417–426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Duewell P, Kono H, Rayner KJ and Latz E:
NLRP3 inflammasomes are required for atherogenesis and activated by
cholesterol crystals. Nature. 464:1357–1361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baroja-Mazo A, Martín-Sánchez F, Gomez AI,
Martínez CM, Amores-Iniesta1 J, Compan V, Barberà-Cremades M, Yagüe
J, Ruiz-Ortiz E, Antón J, et al: The NLRP3 inflammasome is released
as a particulate danger signal that amplifies the inflammatory
response. Nat Immunol. 15:738–748. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Franklin BS, Bossaller L, De Nardo D,
Ratter JM, Stutz A, Engels G, Brenker C, Nordhoff M, Mirandola SR,
Al-Amoudi A, et al: The adaptor ASC has extracellular and
‘prionoid’ activities that propagate inflammation. Nat Immunol.
15:727–737. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amin J, Boche D and Rakic S: What do we
know about the inflammasome in humans? Brain Pathol. 27:192–204.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sutterwala FS, Haasken S and Cassel SL:
Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci.
1319:82–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Danielski LG, Giustina AD, Bonfante S,
Barichello T and Petronilho F: The NLRP3 inflammasome and its role
in sepsis development. Inflammation. 43:24–31. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhong Y, Lu Y, Yang X, Tang Y, Zhao K,
Yuan C and Zhong X: The roles of NLRP3 inflammasome in bacterial
infection. Mol Immunol. 122:80–88. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang H, He H, Chen Y, Huang W, Cheng J,
Ye J, Wang A, Tao J, Wang C, Liu Q, et al: Identification of a
selective and direct NLRP3 inhibitor to treat inflammatory
disorders. J Exp Med. 214:3219–3238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang Y, Jiang H, Chen Y, Wang X, Yang Y,
Tao J, Deng X, Liang G, Zhang H, Jiang W and Zhou R: Tranilast
directly targets NLRP3 to treat inflammasome-driven diseases. EMBO
Mol Med. 10:e86892018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang P, Tsuchiya K, Kinoshita T,
Kushiyama H, Suidasari S, Hatakeyama M, Imura H, Kato N and Takashi
S: Vitamin B6 prevents IL-1β protein production by inhibiting NLRP3
inflammasome activation. J Biol Chem. 291:24517–24527. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li PL: Cardiovascular pathobiology of
inflammasomes: Inflammatory machinery and beyond. Antioxid Redox
Signal. 22:1079–1083. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Umeadi C, Kandeel F and Al-Abdullah IH:
Ulinastatin is a novel protease inhibitor and neutral protease
activator. Transplant Proc. 40:387–389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu CE, Zhang MY, Zou CW and Guo L:
Evaluation of the pharmacological function of ulinastatin in
experimental animals. Molecules. 17:9070–9080. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu Q, Yan Q and Chen S: Use of ulinastatin
was associated with reduced mortality in critically ill patients
with sepsis. J Thorac Dis. 11:1911–1918. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu Q, Yan Q and Chen S: Ulinastatin is
effective in reducing mortality for critically ill patients with
sepsis: A causal mediation analysis. Sci Rep. 8:143602018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals, . Guide for the Care and Use of Laboratory Animals, 8th
edition. National Academies Press (US); Washington, DC: 2011
|
|
23
|
Rittirsch D, Huber-Lang MS, Flierl MA and
Ward PA: Immunodesign of experimental sepsis by cecal ligation and
puncture. Nat Protoc. 4:31–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Otero-Antón E, González-Quintela A,
López-Soto A, López-Ben S, Llovo J and Pérez LF: Cecal ligation and
puncture as a model of sepsis in the rat: Influence of the puncture
size on mortality, bacteremia, endotoxemia and tumor necrosis
factor alpha levels. Eur Surg Res. 33:77–79. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gonnert FA, Recknagel P, Seidel M, Jbeily
N, Dahlke K, Bockmeyer CL, Winning J, Lösche W, Claus RA and Bauer
M: Characteristics of clinical sepsis reflected in a reliable and
reproducible rodent sepsis model. J Surg Res. 170:e123–e134. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Paik S, Kim JK, Silwal P, Sasakawa C and
Jo EK: An update on the regulatory mechanisms of NLRP3 inflammasome
activation. Cell Mol Immunol. 18:1141–1160. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Uemura K, Murakami Y, Hayashidani Y and
Sueda T, Hashimoto Y, Ohge H and Sueda T: Randomized clinical trial
to assess the efficacy of ulinastatin for postoperative
pancreatitis following pancreaticoduodenectomy. J Surg Oncol.
98:309–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao C, Huan J, Li W and Tang J: Protective
effects of ulinastatin on pancreatic and renal damage in rats
following early scald injury. Burns. 35:547–552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng C, Yang H, Huang S and Li T: Early
local drug therapy for pancreatic contusion and laceration.
Pancreatology. 19:285–289. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Atal SS and Atal S: Ulinastatin-a newer
potential therapeutic option for multiple organ dysfunction
syndrome. J Basic Clin Physiol Pharmacol. 27:91–99. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Zhou J and Bai S: Combination of
glutamine and ulinastatin treatments greatly improves sepsis
outcomes. J Inflamm Res. 13:109–115. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karnad DR, Bhadade R, Verma PK, Moulick
ND, Daga MK, Chafekar ND and Iyer S: Intravenous administration of
ulinastatin (human urinary trypsin inhibitor) in severe sepsis: A
multicenter randomized controlled study. Intensive Care Med.
40:830–838. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Masuda T, Sato K, Noda C, Noda C, Ikeda
KM, Matsunaga A, Ogura MN, Shimizu K, Nagasawa H, Matsuyama N and
Izumi T: Protective effect of urinary trypsin inhibitor on
myocardial mitochondria during hemorrhagic shock and reperfusion.
Crit Care Med. 31:1987–1992. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bozza FA, Salluh JI, Japiassu AM, Soares
M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC and Bozza PT:
Cytokine profiles as markers of disease severity in sepsis: A
multiplex analysis. Crit Care. 11:R492007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Van der Poll T, Van de Veerdonk FL,
Scicluna BP and Netea MG: The immunopathology of sepsis and
potential therapeutic targets. Nat Rev Immunol. 17:407–420. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cannon JG, Tompkins RG, Gelfand JA, Michie
HR, Stanford GG, van der Meer JW, Endres S, Lonnemann G, Corsetti
J, Chernow B, et al: Circulating interleukin-1 and tumor necrosis
factor in septic shock and experimental endotoxin fever. J Infect
Dis. 161:79–84. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Girardin E, Grau GE, Dayer JM,
Roux-Lombard P and Lambert PH: Tumor necrosis factor and
interleukin-1 in the serum of children with severe infectious
purpura. N Engl J Med. 319:397–400. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hedayat M, Mahmoudi MJ, Rose NR and Rezaei
N: Proinflammatory cytokines in heart failure: Double-edged swords.
Heart Fail Rev. 15:543–562. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hunter JD and Doddi M: Sepsis and the
heart. Br J Anaesth. 104:3–11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kumar A, Thota V, Dee L, Olson J, Uretz E
and Parrillo JE: Tumor necrosis factor alpha and interleukin 1beta
are responsible for in vitro myocardial cell depression induced by
human septic shock serum. J Exp Med. 183:949–958. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cao YZ, Tu YY, Chen X and Liu MH:
Protective effect of Ulinastatin against murine models of sepsis:
Inhibition of TNF-α and IL-6 and augmentation of IL-10 and IL-13.
Exp Toxicol Pathol. 64:543–547. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hu CL, Li H, Xia JM, Li X, Zeng X, Liao
XX, Zhan H, Jing XL and Dai G: Ulinastatin improved cardiac
dysfunction after cardiac arrest in New Zealand rabbits. Am J Emerg
Med. 31:768–774. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fromm RE Jr: Cardiac troponins in the
intensive care unit: Common causes of increased levels and
interpretation. Crit Care Med. 35:584–588. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Charpentier J, Luyt CE, Fulla Y,
Vinsonneau C, Cariou A, Grabar S, Dhainaut JF, Mira JP and Chiche
JD: Brain natriuretic peptide: A marker of myocardial dysfunction
and prognosis during severe sepsis. Crit Care Med. 32:660–665.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li N, Zhou H, Wu H, Wu Q, Duan M, Deng W
and Tang Q: STING-IRF3 contributes to lipopolysaccharide-induced
cardiac dysfunction, inflammation, apoptosis and pyroptosis by
activating NLRP3. Redox Biol. 24:1012152019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
He Y, Hara H and Núñez G: Mechanism and
regulation of NLRP3 inflammasome activation. Trends Biochem Sci.
41:1012–1021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Linder A and Russell JA: An exciting
candidate therapy for sepsis: Ulinastatin, a urinary protease
inhibitor. Intensive Care Med. 40:1164–1167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang N, Lui X, Zheng X, Cao H, Wei G, Zhu
Y, Fan S, Zhou H and Zheng J: Ulinastatin is a novel candidate drug
for sepsis and secondary acute lung injury, evidence from an
optimized CLP rat model. Int Immunopharmacol. 17:799–807. 2013.
View Article : Google Scholar : PubMed/NCBI
|
